Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Chief Financial Officer | June 24, 2026 | June 24, 2026 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director | June 10, 2026 | June 12, 2026 |
| PDS Biotechnology CorpPDSB · Entity 7939 | Director · Chief Financial Officer | February 14, 2020 | February 19, 2020 |
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Chief Financial Officer | May 28, 2021 | June 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date June 24, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 187,432 |
Reported balance
After 2026-06-24 transaction · row 1
1 source rowRow 1 · 2026-06-24 · Sale · Disposed 5,696 · Balance 187,432 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on June 24, 2024, pursuant to a durable sale instruction. The sale does not represent a discretionary trade. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on June 24, 2024, pursuant to a durable sale instruction. The sale does not represent a discretionary trade.
Milestone Pharmaceuticals Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-10 | Direct | 77,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,000 · Balance 77,000 F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
PDS Biotechnology Corp
Report date February 14, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,549 |
Reported balance
After 2020-02-14 transaction · row 1
1 source rowRow 1 · 2020-02-14 · Grant · Acquired 38,400 · Balance 42,549 F1: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on February 14, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on February 14, 2020.
Yarrow Bioscience, Inc.
Report date May 28, 2021 · Filed June 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,468 |
Reported balance
After 2021-05-28 transaction · row 1
1 source rowRow 1 · 2021-05-28 · Grant · Acquired 3,017 · Balance 116,468 F1: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2020 and ending on May 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on May 28, 2021 (the last trading day of the offering period). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2020 and ending on May 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on May 28, 2021 (the last trading day of the offering period).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 23,021 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 45,244 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.44 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 17,600 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.40 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 24,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.84 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 72,540 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 24, 2026 21:20 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 5,696 | $8.16 | $46,473.66 |
DisclosureSEC source: 0001628280-26-045286 · wk-form4_1782336014.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,432 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on June 24, 2024, pursuant to a durable sale instruction. The sale does not represent a discretionary trade. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001616284-26-000002 · form4-06122026_040612.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:18 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 11,139 | $9.94 | $110,692.70 |
DisclosureSEC source: 0001628280-26-034615 · wk-form4_1778703501.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,128 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:58 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0001628280-26-013531 · wk-form4_1772503133.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2036-02-25 F2 · derivative.exercise_date: The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:58 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013531 · wk-form4_1772503133.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,267 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 23:14 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 5,134 | $11.89 | $61,043.26 |
DisclosureSEC source: 0001628280-26-009306 · wk-form4_1771456485.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,267 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade. Read SEC document |
| June 24, 2025 Filed Jun 24, 2025 20:08 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 5,700 | $7.61 | $43,377.00 |
DisclosureSEC source: 0001655759-25-000109 · wk-form4_1750795707.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,401 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on June 24, 2024. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:19 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001415889-25-016933 · form4-06122025_040612.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2025, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:17 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 91,000 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001655759-25-000091 · wk-form4_1747171064.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2035-05-08 F2 · derivative.exercise_date: The option was granted by the Issuer on May 9, 2025, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:17 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 59,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-25-000091 · wk-form4_1747171064.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,101 F1 · shares: The restricted stock units (each, an "RSU") were granted by the issuer on May 9, 2025, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 00:59 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 74,960 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001655759-25-000027 · wk-form4_1739926780.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,960 Underlying: Common Stock · 74,960 shares Expires 2035-02-12 F2 · derivative.exercise_date: The option was granted by the Issuer on February 13, 2025, pursuant to the Plan. The shares underlying the option vest over four years: 1/4 of the shares underlying the award will vest on February 13, 2026, with the remainder of the shares vesting in equal monthly installments following February 13, 2026 through February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 00:59 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 49,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-25-000027 · wk-form4_1739926780.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,501 F1 · shares: The restricted stock units (each, an "RSU") were granted by the issuer on February 13, 2025, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of February 13, 2026, February 13, 2027, February 13, 2028 and February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001415889-24-022537 · form4-08292024_040813.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-08-28 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on September 28, 2024, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:17 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-019668 · form4-07172024_080740.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: This option will vest in equal monthly installments, beginning on August 15, 2024, over a period of three years, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:20 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 94,418 | $0.00 Strike: $24.97 | $0.00 |
DisclosureSEC source: 0001655759-24-000105 · wk-form4_1719433252.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,418 Underlying: Common Stock · 94,418 shares Expires 2034-06-23 F2 · derivative.exercise_date: The option was granted by the Issuer on June 24, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant the Plan. The shares underlying the option will vest over four years: 1/4 of the shares underlying the award shall vest on June 24, 2025, with the remainder of the shares vesting in equal monthly installments following June 24, 2025 through June 24, 2028. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:20 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 61,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-24-000105 · wk-form4_1719433252.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,409 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), and not pursuant to its 2018 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of June 24, 2025, June 24, 2026, June 24, 2027 and June 24, 2028, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:40 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 72,540 | Not disclosed Strike: $20.84 | Not disclosed |
DisclosureSEC source: 0001104659-23-117093 · tm2330435-1_4seq1.xml · derivative · entry 5 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,540 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:40 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 24,000 | Not disclosed Strike: $18.40 | Not disclosed |
DisclosureSEC source: 0001104659-23-117093 · tm2330435-1_4seq1.xml · derivative · entry 4 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:40 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 17,600 | Not disclosed Strike: $14.44 | Not disclosed |
DisclosureSEC source: 0001104659-23-117093 · tm2330435-1_4seq1.xml · derivative · entry 3 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,600 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:40 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerCommon Stock | 45,244 | $19.00 | $859,636.00 |
DisclosureSEC source: 0001104659-23-117093 · tm2330435-1_4seq1.xml · nonDerivative · entry 2 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:40 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | OtherCommon Stock | 23,021 | $19.00 | $437,399.00 |
DisclosureSEC source: 0001104659-23-117093 · tm2330435-1_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 908 | $10.80 | $9,806.40 |
DisclosureSEC source: 0001104659-23-103508 · tm2326871-1_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,265 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 16:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 908 | $11.74 | $10,659.92 |
DisclosureSEC source: 0001104659-23-074233 · tm2319483-1_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,173 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 909 | $14.19 | $12,898.71 |
DisclosureSEC source: 0001104659-23-036043 · tm2310362-1_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,081 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 16:05 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 24,000 | $0.00 Strike: $18.40 | $0.00 |
DisclosureSEC source: 0001104659-23-008588 · tm234878-6_4seq1.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-01-27 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 16:05 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 14,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-008588 · tm234878-6_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,990 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 16:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 718 | $12.37 | $8,881.66 |
DisclosureSEC source: 0001104659-23-000337 · tm231319-6_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,290 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 16:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 908 | $13.43 | $12,194.44 |
DisclosureSEC source: 0001104659-22-129883 · tm2233418-1_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,008 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 16:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 908 | $14.85 | $13,483.80 |
DisclosureSEC source: 0001104659-22-102662 · tm2226480-1_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,916 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 3,632 | $12.48 | $45,327.36 |
DisclosureSEC source: 0001104659-22-073886 · tm2219176-1_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,824 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 16:16 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 17,600 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001104659-22-009563 · tm224882-8_4seq1.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2032-01-27 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 16:16 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 10,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-009563 · tm224882-8_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,456 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 72,540 | $0.00 Strike: $20.84 | $0.00 |
DisclosureSEC source: 0001104659-21-084279 · tm2120362-2_4seq1.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,540 Underlying: Common Stock · 72,540 shares Expires 2031-06-21 F2 · derivative.exercise_date: 1/4th of the options subject to the award will vest and become exercisable on the first anniversary of the Vesting Commencement Date, and the remaining options will vest and become exercisable in equal monthly installments in arrears over the three-year period commencing on the first anniversary of the Vesting Commencement Date and ending on the fourth anniversary of the Vesting Commencement Date. The Vesting Commencement Date is June 21, 2021. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 52,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-084279 · tm2120362-2_4seq1.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,156 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the shares subject to the award will vest on the first anniversary of the Vesting Commencement Date, and the remaining shares will vest in equal quarterly installments in arrears over the three-year period commencing on the first anniversary of the Vesting Commencement Date and ending on the fourth anniversary of the Vesting Commencement Date. The Vesting Commencement Date is June 21, 2021. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:31 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 3,017 | $3.36 | $10,129.58 |
DisclosureSEC source: 0001209191-21-037193 · doc4.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,468 F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2020 and ending on May 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on May 28, 2021 (the last trading day of the offering period). Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:14 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | Tax withholdingCommon Stock | 762 | $6.84 | $5,212.08 |
DisclosureSEC source: 0001209191-21-024410 · doc4.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,451 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:39 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 68,162 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001209191-21-013814 · doc4.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,162 Underlying: Common Stock · 68,162 shares Expires 2031-02-22 F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:39 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantCommon Stock | 29,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013814 · doc4.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,213 F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. F2 · shares: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 00:01 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 40,000 | $1.46 | $58,480.00 |
DisclosureSEC source: 0001209191-20-049796 · doc4.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 F1 · price: These shares were purchased in multiple transactions at prices ranging from $1.4499 to $1.4767 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 250,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001209191-20-028037 · doc4.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-05-06 F2 · derivative.exercise_date: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-028037 · doc4.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc. F2 · shares: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024. Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 20:31 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001209191-20-020935 · doc4.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-03-23 F2 · derivative.exercise_date: The option will vest and become exercisable over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter), ending March 31, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 20:31 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020935 · doc4.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Reflects restricted stock units, each of which represents a contingent right to receive one share of Issuer common stock, subject to continued service to the Issuer. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:30 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantCommon Stock | 38,400 | $1.30 | $49,920.00 |
DisclosureSEC source: 0001140361-20-003645 · form4.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,549 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on February 14, 2020. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 21:41 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 62,715 | $0.00 Strike: $6.39 | $0.00 |
DisclosureSEC source: 0001127602-19-021141 · form4.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,715 Underlying: Common Stock · 62,715 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 62,715 shares of Common Stock, will become exercisable on June 6, 2020, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 21:55 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionRestricted Stock Units · Derivative | 82,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-011939 · form4.xml · derivative · entry 2 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F3 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F4 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 21:55 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionCommon Stock | 82,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-011939 · form4.xml · nonDerivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 11:57 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantRestricted Stock Units · Derivative | 82,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-025368 · form4.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,999 Underlying: Common Stock · 82,999 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F2 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F3 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:19 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 166,001 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021571 · form4.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,001 Underlying: Common Stock · 166,001 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 13:27 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 50,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009814 · form4.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 50,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.